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Elevated levels of a circulating form of the transforming growth factor-β (TGF-β) coreceptor endoglin correlate 
with poor clinical outcome in different types of cancer. Soluble endoglin (Sol-Eng) is primarily produced by 
cleavage of cell-surface endoglin by the transmembrane metalloprotease MMP14 that releases most of its 
extracellular domain. Sol-Eng has been found to contribute to different cardiovascular pathologies, including 
preeclampsia, a severe hypertensive syndrome of pregnancy. While the anti-angiogenic and pro-hypertensive 
functions of Sol-Eng appear well established, its role in cancer has not been fully investigated. Recently, we 
reported that Sol-Eng strongly inhibits signaling through the hepatocyte growth factor (HGF) tyrosine kinase 
receptor Met in mouse skin spindle carcinoma cells. Sol-Eng also blocked basal and HGF-mediated stimulation 
of carcinoma cell proliferation, migration and invasion. Taken together, the above results and the 
anti-angiogenic function exerted by Sol-Eng suggest a suppressor role for Sol-Eng in cancer. This conclusion is 
discussed in the paradoxical context of Sol-Eng as a marker of poor prognosis and as a potential contributor to 
the decreased risk of preeclamptic mothers to develop breast cancer later in life. 
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Endoglin (CD105) is a 180-kDa homodimeric 
transmembrane glycoprotein that behaves as an auxiliary 
receptor for the transforming growth factor-β (TGF-β) family 
of cytokines. It binds TGF-β1, TGF-β3, activin-A, and bone 
morphogenetic proteins (BMPs) BMP2, BMP9 and BMP10 
[1], and plays a crucial role in hematopoiesis, cardiovascular 
development, vascular remodeling and angiogenesis [2, 3]. 
Accordingly, Endoglin-deficient mice (Eng-/-) die at 
midgestation as a result of cardiovascular abnormalities [4, 5]. 
The Endoglin gene is mutated in hereditary haemorrhagic 
telangiectasia type I (HHT1), a vascular disorder historically 
known as the Osler-Weber-Rendu syndrome. HHT patients 
display arteriovenous malformations that result in cutaneous 
telangiectasias and nose and gastrointestinal bleeds, more 
dangerous and threatening when occur in large vessels of the 
liver, brain and lungs [6, 7].  
Endoglin plays an important role in cancer at two different 
levels: i) in endothelial cells as a regulator of tumor 
angiogenesis; and ii) in tumor cells as a modulator of 
malignancy [1, 8]. Expression of endoglin is high in peri- 
tumoral and intratumoral blood vessels of different types of 
cancer and has proved to be a useful target for tumor imaging 
and antiangiogenic therapy. Indeed, humanized anti- 
endoglin antibodies are currently being explored to destroy 
the tumor vasculature and halt tumor cell growth [9, 10]. 
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Table 1. Ligands binding to Sol-Eng 
Ligand Procedure/Reference Comments 
TGF-β1 Interference with binding of 
radiolabeled TGF-β1 to TβRII32 
No direct binding was 
assessed 
SPR34 Sol-Eng directly binds 




SPR33-35 Sol-Eng directly binds 
BMP9 with high 
affinity 
BMP10 SPR33 Sol-Eng directly binds 




Interference with endoglin-mediated 
adhesion to β1 integrin of 
leukocytes24 
No direct binding was 
assessed 
Met Coimmunoprecipitation47 No direct binding was 
assessed 
TβRII, TGF-β type II receptor; SPR, surface plasmon resonance 
Endoglin expression has also been detected in cancer cells, 
where it modulates tumor cell proliferation, invasion and 
metastasis. Thus, endoglin behaves not only as a tumor 
suppressor in esophageal, prostate and breast carcinomas 
[11-13], but also as a promoter of malignancy in melanoma and 
Ewin sarcoma [14]. Moreover, endoglin appears to contribute 
to chemotherapy resistance in ovarian and pancreatic cancer 
[15, 16]. In a pioneer work, we demonstrated a dual role for 
endoglin during multistage mouse skin carcinogenesis in vivo 
[17, 18]. The skin of endoglin haploinsufficient mice (Eng+/-) 
was subjected to a single topical dose of 
7,12-dimethylbenz(a)anthracene (DMBA) followed by twice 
a week treatment with the tumor promoter 
12-O-tetradecanoylphorbol-13-acetate (TPA). This protocol 
induces the outgrowth of benign papillomas after several 
weeks of initiation with DMBA, from which a small 
proportion progress to malignant squamous cell carcinomas. 
Eng+/- mice developed a lesser number of tumors than 
wild-type mice, but progression to carcinomas in these 
endoglin haploinsufficient mice was vastly accelerated and a 
substantial proportion of tumors were classified as highly 
aggressive undifferentiated spindle cell carcinomas. The 
tumor phenotype of Eng+/- mice was quite similar to that of 
transgenic mice with targeted expression of TGF-β1 in the 
epidermis[19], a result that provided the proof-of-concept for 
the double and contradictory role of TGF-β1 in cancer as a 
suppressor at early stages of carcinogenesis and a stimulator 
of malignancy at later stages [20, 21].  
Structurally, the extracellular (EC) region of endoglin is 
composed of an orphan domain and a zona pellucida (ZP) 
domain[2]. It is highly glycosylated, containing five potential 
N-linked sites within the orphan domain, and a putative 
O-glycan motif in the ZP domain proximal to the 
transmembrane region (Figure 1). An Arg-Gly-Asp (RGD) 
peptide within the ZP domain of human endoglin constitutes 
a prototypic member of a family of motifs involved in 
integrin-based interactions between the extracellular matrix 
and certain cell surface proteins [22, 23]. It has been 
demonstrated that membrane-bound endoglin interacts with 
integrin α5β1 via its RGD motif [24, 25]. The RGD motif is 
present in endoglin from primates, while functionally related 
RGD-like motifs are found in endoglin from other animals, 
stressing the physiological importance and conservation of 
this motif [22, 24]. It has been reported [26, 27] that the 
membrane-bound matrix metalloprotease-14 (MMP-14), also 
known as MT1-MMP, cleaves the EC region of endoglin at a 
juxtamembrane site, releasing a circulating form termed 
soluble endoglin (Sol-Eng).  
The body fluids (plasma, serum and urine) from patients 
with preeclampsia, hypercholesterolemia, atherosclerosis and 
cancer contain high levels of Sol-Eng [1, 8, 28, 29]. Furthermore, 
Sol-Eng is a marker of cardiovascular damage in patients 
suffering of hypertension and diabetes [30]. Preeclampsia is a 
systemic syndrome affecting 3-5% of pregnancies 
characterized by hypertension and proteinuria, which results 
in significant morbidity and mortality to both mothers and 
fetuses [28]. Interestingly, preeclamptic placentas express 
MMP14 that apparently mediates the release of Sol-Eng[31]. 
It has been reported that Sol-Eng plays an antagonistic role 
with respect to membrane endoglin as an anti-angiogenic and 
pro-hypertensive molecule by interacting with cytokines of 
the TGF-β family [26, 27. 32]. Sol-Eng impairs endothelial cell 
proliferation, capillary formation and blood vessel sprouting 
[26, 32, 33], and increases blood pressure and vascular 
permeability [27, 32].  In addition, Sol-Eng may inhibit the 
anti-atherogenic effects induced by TGF-β [29], and alter 
vascular homeostasis by scavenging TGF-β1, thus preventing 
its binding to endothelial cell surface receptors [32]. However, 
this issue remains controversial as there are reports 
demonstrating that Sol-Eng binds with high affinity BMP9 
and BMP10, but not TGF-β1 and TGF-β3 [33-35] (Table 1). 
Elevated levels of Sol-Eng are found in breast, colorectal 
and prostate cancer patients associated with tumor 
progression and metastasis [36-40].  In addition, high levels of 
Sol-Eng are detected in the plasma of patients with lung 
cancer [41], and correlate with proliferation and angiogenesis 
in myeloid malignancies [42-44]. In a mouse skin chemical 
carcinogenesis model, we found that endoglin is shed from 
both endothelial and tumor cells, and that release of Sol-Eng 
into the tumor stroma and the blood stream is associated with 
advanced stages of tumor progression [45]. Therefore, it can 
be postulated that Sol-Eng interacts with different proteins in 
the extracellular matrix as well as on the surface of stromal 
and tumor cells. An interesting cross-talk between the tumor 
and the stroma, using an in vitro cellular system, has been 
reported [46]. This model involves the cleavage of membrane 
endoglin and the subsequent release of Sol-Eng from MCF-7 
breast cancer cells by soluble MMP14 originated from bone 
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marrow-derived stromal cells. Production of soluble MMP14 
is likely triggered by the action of TGF-β1, which is secreted 
by MCF-7 tumor cells, initiating a cycle of heterotypic 
interactions tumor-stroma that results in increased 
malignancy of breast cancer cells [46]. This study also points 
out that a direct interaction between membrane-bound 
MMP14 and endoglin on the cell surface is not a strict 
requirement for endoglin shedding [26]. However, the effect 
of Sol-Eng on the behavior of tumor and stromal cells was 
not investigated in this study. 
In a recent article, we explored whether Sol-Eng affects 
the malignant properties of highly aggressive skin spindle 
carcinoma cells [47]. We found that Sol-Eng inhibits 
carcinoma cell proliferation, as wells as basal and 
TGF-β1-stimulated mitogen-activated protein kinase 
(MAPK) signaling activity. A marked inhibitory effect of 
Sol-Eng on in vitro carcinoma cell growth was observed. By 
contrast, only a mild inhibition was seen in vivo, when 
measuring the growth of tumors induced by transplantation 
of carcinoma cells in athymic nude mice, suggesting that 
undefined effects of Sol-Eng on stromal cells may counteract 
the growth inhibition directly imposed upon tumor cells 
(Figure 1). At variance with these results, a strong inhibitory 
effect of the EC domain of endoglin fused to an 
immunoglobulin Fc domain on the growth of colon 
adenocarcinoma cells subcutaneously implanted in mice was 
found [33]. A characteristic of skin spindle carcinomas shared 
by other types of advanced tumors, including basal breast 
carcinomas, is the secretion of high levels of hepatocyte 
growth factor (HGF) and hyperactivation of Met, its tyrosine 
kinase receptor. Of note, Sol-Eng strongly inhibited both 
basal and HGF-induced Met activation and downstream 
MAPK signaling activity as well as basal and 
HGF-stimulated carcinoma cell migration and invasion [47]. 
The mechanism for this action is unclear and may involve the 
binding of Sol-Eng to Met on the cell surface, preventing its 
HGF-mediated activation and dimerization, but promoting its 
internalization and degradation independently of HGF. 
Interestingly, full-length membrane endoglin also binds Met, 
as shown by coimmunoprecipitation experiments, but it is 
unable to influence Met stability and signaling activity [47]. 
Recent studies indicate that the binding of Sol-Eng to Met is 
not direct (our unpublished results) and might be mediated 
by some of the proteins that associate with Met in a 
multiprotein complex at the plasma membrane, such as 
plexins, the hyaluronan receptor CD44 or integrins [48]. In 
this regard, membrane endoglin in endothelial cells interacts 
Figure 1. Structure of soluble endoglin and its function in cancer related cells. Left, schematic 
representation of the release of Sol-Eng after proteolytic cleavage of membrane-bound endoglin. Endoglin 
contains an orphan domain and a zona pellucida (ZP) domain within the extracellular region. Potential, 
N-glycosylations in the orphan domain and O-glycosylation in the ZP domain are indicated by purple dots. 
The purple pentagon in the ZP domain represents the RGD tripeptide sequence involved in the binding of 
endoglin to integrins. The known and unknown effects of Sol-Eng on tumor and stromal cells are indicated 
on the right. The tumor stroma contains endothelial cells, pericytes, fibroblasts, neutrophils, macrophages, 
mast cells and dendritic cells, among others. Whereas several studies have reported effects of Sol-Eng on 
the behavior of tumor and endothelial cells, it remains to be investigated the action of Sol-Eng on the rest of 
stromal cells. For additional details see the text. CAF, cancer-associated fibroblasts. 
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with α5β1 integrin via its RGD motif contained within the 
ZP domain [24, 25]. Moreover, endoglin-mediated cell 
adhesion is involved in endothelial transmigration of 
leukocytes and is abolished by Sol-Eng [24], suggesting that 
Sol-Eng competes with membrane endoglin for binding to β1 
integrins. It will be of interest to determine whether Sol-Eng 
binds to the integrin partners of Met. A number of proteins 
able to interact with membrane-bound endoglin has been 
described [1, 2]. A summary of some of the ligands reported to 
bind Sol-Eng in vitro is presented in Table 1, while the 
identification of ligands interacting with Sol-En in vivo 
should be a priority objective for those researchers interested 
in understanding the function of Sol-Eng in cancer and other 
pathologies.  
Altogether, the anti-angiogenic and anti-oncogenic effects 
of Sol-Eng described above suggest a suppressor role for this 
circulating form of endoglin in carcinogenesis. This 
conclusion appears paradoxical taking into account the direct 
correlation between elevated levels of circulating endoglin 
and poor prognosis in different types of human cancer [1, 8]. 
Because the increased production of Sol-Eng in the tumor 
microenvironment appears to be a late event in malignant 
progression [45], an explanation for this apparent discrepancy 
is that, at this late stage, Sol-Eng present in the 
microenvironment cannot counteract the full malignant 
potential displayed by advanced tumors. By contrast, 
Sol-Eng should have a protective role for tumor formation at 
early stages of cancer development, as inferred from its 
tumor suppressor function. Indeed, epidemiological evidence 
indicates that preeclamptic pregnancy is associated with a 
lower risk for both the mother and offspring to develop 
breast cancer later in life [49, 50]. Noteworthy, the levels of 
Sol-Eng are reportedly to be elevated not only at 
preeclampsia, but also many years after preeclamptic 
pregnancies [49]. It should be mentioned, however, that some 
reports failed to find out a correlation between cancer 
incidence and preeclampsia [49, 50]. Notwithstanding, serum 
from pregnant rats with placental ischemia (regarded as the 
primary initiating factor of preeclampsia) and 
preeclamptic-like symptoms, as well as purified Sol-Eng 
inhibit the proliferation of breast cancer cells in vitro[50], 
supporting the tumor suppressor role of Sol-Eng. These 
results are in agreement with our own data in skin carcinoma 
cells [47]. Based on these findings, it has been postulated that 
reduction of mammary progenitor cells and attenuation of 
TGF-β signaling mediated by persistently elevated levels of 
circulating factors, such as Sol-Eng, underlines the protective 
effect of preeclampsia on breast cancer [50]. Nevertheless, the 
precise molecular and cellular mechanisms of this correlation 
remain to be elucidated. 
In summary, the results from a number of laboratories, 
including ours, suggest a suppressor role for Sol-Eng in 
tumor progression. Accordingly, Sol-Eng can be proposed as 
a potential new tool for therapeutic intervention in cancer. 
Since cancer involves a continuous cycle of deregulated 
tissue injury and repair, resembling in many aspects chronic 
fibrosis and wound healing responses [51], the potential 
involvement of Sol-Eng in these processes remains to be 
investigated. In this sense, MMP14, the primary 
metalloprotease responsible for the release of Sol-Eng, 
appears to play an important role in pulmonary fibrosis [52] 
and in mediating the crosstalk between epidermis and dermis 
during skin repair [53].  
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